Protopanaxadiol, an active ginseng metabolite, significantly enhances the effects of fluorouracil on colon cancer

Nutrients

Volumn 7, Issue 2, 2015, Pages 799-814

  Wang, Chong Zhi ^a,b   Zhang, Zhiyu ^a,b   Wan, Jin Yi ^a   Zhang, Chun Feng ^a,b   Anderson, Samantha ^a,b   He, Xin ^a   Yu, Chunhao ^a,b   He, Tong Chuan ^b   Qi, Lian Wen ^a   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Athymic mice; Cell cycle; Cell proliferation; Colorectal cancer; Enteric microbiome; Fluorouracil; Ginseng; HCT 116 cells; Metabolite; Protopanaxadiol; Xenograft

Indexed keywords

FLUOROURACIL; PROTOPANAXADIOL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; SAPOGENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG PURITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MASS SPECTROMETRY; MICROBIOME; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR WEIGHT; ULTRAVIOLET SPECTROSCOPY; WHOLE BODY IMAGING; ANIMAL; CHEMISTRY; COLONIC NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; EVALUATION STUDY; HCT116 CELL LINE; NUDE MOUSE; PANAX; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

MUS; PANAX GINSENG;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FLUOROURACIL; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; PANAX; SAPOGENINS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921858255     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7020799     Document Type: Article

References (42)

1. Attele, A.S.; Wu, J.A.; Yuan, C.S. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58, 1685-1693.
2. Qi, L.W.; Wang, C.Z.; Yuan, C.S. Isolation and analysis of ginseng: Advances and challenges. Nat. Prod. Rep. 2011, 28, 467-495.
3. Park, E.Y.; Kim, M.H.; Kim, E.H.; Lee, E.K.; Park, I.S.; Yang, D.C.; Jun, H.S. Efficacy comparison of Korean ginseng and American ginseng on body temperature and metabolic parameters. Am. J. Chin. Med. 2014, 42, 173-187.
4. Qi, L.W.; Wang, C.Z.; Yuan, C.S. Ginsenosides from American ginseng: Chemical and pharmacological diversity. Phytochemistry 2011, 72, 689-699.
5. Qi, L.W.; Wang, H.Y.; Zhang, H.; Wang, C.Z.; Li, P.; Yuan, C.S. Diagnostic ion filtering to characterize ginseng saponins by rapid liquid chromatography with time-of-flight mass spectrometry. J. Chromatogr. A 2012, 1230, 93-99.
6. Yun, T.K.; Choi, S.Y. Preventive effect of ginseng intake against various human cancers: A case-control study on 1987 pairs. Cancer Epidemiol. Biomark. Prev. 1995, 4, 401-408.
7. Yun, T.K. Panax ginseng—A non-organ-specific cancer preventive? Lancet Oncol. 2001, 2, 49-55.
8. Wang, C.Z.; Zhang, B.; Song, W.X.; Wang, A.; Ni, M.; Luo, X.; Aung, H.H.; Xie, J.T.; Tong, R.; He, T.C. et al. Steamed American ginseng berry: Ginsenoside analyses and anticancer activities. J. Agric. Food Chem. 2006, 54, 9936-9942.
9. Wang, C.Z.; Aung, H.H.; Ni, M.; Wu, J.A.; Tong, R.; Wicks, S.; He, T.C.; Yuan, C.S. Red American ginseng: Ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med. 2007, 73, 669-674.
10. Wang, C.Z.; Du, G.J.; Zhang, Z.; Wen, X.D.; Calway, T.; Zhen, Z.; Musch, M.W.; Bissonnette, M.; Chang, E.B.; Yuan, C.S. Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int. J. Oncol. 2012, 40, 1970-1976.
11. Gao, J.L.; Lv, G.Y.; He, B.C.; Zhang, B.Q.; Zhang, H.; Wang, N.; Wang, C.Z.; Du, W.; Yuan, C.S.; He, T.C. Ginseng saponin metabolite 20(S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways. Oncol. Rep. 2013, 30, 292-298.
12. Sekirov, I.; Russell, S.L.; Antunes, L.C.; Finlay, B.B. Gut microbiota in health and disease. Physiol. Rev. 2010, 90, 859-904.
13. Holmes, E.; Kinross, J.; Gibson, G.R.; Burcelin, R.; Jia, W.; Pettersson, S.; Nicholson, J.K. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 2012, 4, 137rv6, doi: 10.1126/scitranslmed.3004244.
14. Wan, J.Y.; Liu, P.; Wang, H.Y.; Qi, L.W.; Wang, C.Z.; Li, P.; Yuan, C.S. Biotransformation and metabolic profile of American ginseng saponins with human intestinal microflora by liquid chromatography quadrupole time-of-flight mass spectrometry. J. Chromatogr. A 2013, 1286, 83-92.
15. Dougherty, U.; Mustafi, R.; Wang, Y.; Musch, M.W.; Wang, C.Z.; Konda, V.J.; Kulkarni, A.; Hart, J.; Dawson, G.; Kim, K.E. et al. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: Role of EGFR. BMC Complement. Altern. Med. 2011, 11, 111, doi:10.1186/1472-6882-11-111.
16. Hasegawa, H.; Sung, J.H.; Matsumiya, S.; Uchiyama, M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62, 453-457.
17. Bae, E.A.; Park, S.Y.; Kim, D.H. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol. Pharm. Bull. 2000, 23, 1481-1485.
18. Ott, M.J. Complementary and alternative therapies in cancer symptom management. Cancer Pract. 2002, 10, 162-166.
19. Wang, C.Y.; Bai, X.Y.; Wang, C.H. Traditional Chinese medicine: A treasured natural resource of anticancer drug research and development. Am. J. Chin. Med. 2014, 42, 543-559.
20. Yuan, C.S.; Wei, G.; Dey, L.; Karrison, T.; Nahlik, L.; Maleckar, S.; Kasza, K.; Ang-Lee, M.; Moss, J. Brief communication: American ginseng reduces warfarin’s effect in healthy patients: A randomized, controlled Trial. Ann. Intern. Med. 2004, 141, 23-27.
21. Gu, C.; Qiao, J.; Zhu, M.; Du, J.; Shang, W.; Yin, W.; Wang, W.; Han, M.; Lu, W. Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells. Am. J. Chin. Med. 2013, 41, 443-458.
22. Pinedo, H.M.; Peters, G.F. Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 1988, 6, 1653-1664.
23. Smorenburg, C.H.; Peters, G.J.; van Groeningen, C.J.; Noordhuis, P.; Smid, K.; van Riel, A.M.; Dercksen, W.; Pinedo, H.M.; Giaccone, G. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann. Oncol. 2006, 17, 35-42.
24. Wang, C.Z.; Luo, X.; Zhang, B.; Song, W.X.; Ni, M.; Mehendale, S.; Xie, J.T.; Aung, H.H.; He, T.C.; Yuan, C.S. Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother. Pharmacol. 2007, 60, 69-79.
25. Li, X.L.; Wang, C.Z.; Mehendale, S.R.; Sun, S.; Wang, Q.; Yuan, C.S. Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. Cancer Chemother. Pharmacol. 2009, 64, 1097-1104.
26. Choi, J.R.; Hong, S.W.; Kim, Y.; Jang, S.E.; Kim, N.J.; Han, M.J.; Kim, D.H. Metabolic activities of ginseng and its constituents, ginsenoside rb1 and rg1, by human intestinal microflora. J. Ginseng Res. 2011, 35, 301-307.
27. Kong, H.; Wang, M.; Venema, K.; Maathuis, A.; van der Heijden, R.; van der Greef, J.; Xu, G.; Hankemeier, T. Bioconversion of red ginseng saponins in the gastro-intestinal tract in vitro model studied by high-performance liquid chromatography-high resolution Fourier transform ion cyclotron resonance mass spectrometry. J. Chromatogr. A 2009, 1216, 2195-2203.
28. He, B.C.; Gao, J.L.; Zhang, B.Q.; Luo, Q.; Shi, Q.; Kim, S.H.; Huang, E.; Gao, Y.; Yang, K.; Wagner, E.R. et al. Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol. Pharmacol. 2011, 79, 211-219.
29. Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 104-117.
30. Macarulla, T.; Sauri, T.; Tabernero, J. Evaluation of aflibercept in the treatment of metastatic colorectal cancer. Expert Opin. Biol. Ther. 2014, 14, 1493-1505.
31. Chen, S.; Qu, X.; Wan, P.; Li, Q.W.; Wang, Z.; Guo, F.; Bai, L.; Hu, Z.; Tan, W.; Li, J. Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells. Am. J. Chin. Med. 2013, 41, 665-682.
32. Liu, S.; Wang, X.J.; Liu, Y.; Cui, Y.F. PI3K/AKT/mTOR signaling is involved in (−)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am. J. Chin. Med. 2013, 41, 629-642.
33. Wen, X.D.; Wang, C.Z.; Yu, C.; Zhang, Z.; Calway, T.; Wang, Y.; Li, P.; Yuan, C.S. Salvia miltiorrhiza (dan shen) significantly ameliorates colon inflammation in dextran sulfate sodium induced colitis. Am. J. Chin. Med. 2013, 41, 1097-1108.
34. Tawab, M.A.; Bahr, U.; Karas, M.; Wurglics, M.; Schubert-Zsilavecz, M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos. 2003, 31, 1065-1071.
35. Hasegawa, H. Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid. J. Pharmacol. Sci. 2004, 95, 153-157.
36. Oh, G.S.; Pae, H.O.; Choi, B.M.; Seo, E.A.; Kim, D.H.; Shin, M.K.; Kim, J.D.; Kim, J.B.; Chung, H.T. 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett. 2004, 205, 23-29.
37. Wang, C.Z.; Li, B.; Wen, X.D.; Zhang, Z.; Yu, C.; Calway, T.D.; He, T.C.; Du, W.; Yuan, C.S. Paraptosis and NF-kappaB activation are associated with protopanaxadiol-induced cancer chemoprevention. BMC Complement. Altern. Med. 2013, 13, 2, doi:10.1186/1472-6882-13-2.
38. Wolpin, B.M.; Mayer, R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134, 1296-1310.
39. Meregalli, M.; Martignoni, G.; Frontini, L.; Zonato, S.; Pavia, G.; Beretta, G. Increasing doses of 5-fluorouracil and high-dose folinic acid in the treatment of metastatic colorectal cancer. Tumori 1998, 84, 662-665.
40. Jin, H.R.; Zhao, J.; Zhang, Z.; Liao, Y.; Wang, C.Z.; Huang, W.H.; Li, S.P.; He, T.C.; Yuan, C.S.; Du, W. The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress. Cell Death Dis. 2012, 3, e376, doi:10.1038/cddis.2012.122.
41. Jin, H.R.; Liao, Y.; Li, X.; Zhang, Z.; Zhao, J.; Wang, C.Z.; Huang, W.H.; Li, S.P.; Yuan, C.S.; Du, W. Anticancer compound oplopantriol A kills cancer cells through inducing ER stress and BH3 proteins Bim and Noxa. Cell Death Dis. 2014, 5, e1190, doi:10.1038/cddis.2014.169.
42. Tiffen, J.C.; Bailey, C.G.; Ng, C.; Rasko, J.E.; Holst, J. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol. Cancer 2010, 9, 299, doi:10.1186/1476-4598-9-299.